These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 8867478)

  • 1. [Ciprofloxacin in treatment of common bacterial skin infections. Results of an open study in general practice].
    Braun H
    Fortschr Med; 1996 Feb; 114(5):55-6. PubMed ID: 8867478
    [No Abstract]   [Full Text] [Related]  

  • 2. A multicentre, double-blind, randomised study comparing the efficacy and safety of oral levofloxacin versus ciprofloxacin in the treatment of uncomplicated skin and skin structure infections.
    Nicodemo AC; Robledo JA; Jasovich A; Neto W
    Int J Clin Pract; 1998 Mar; 52(2):69-74. PubMed ID: 9624783
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical ciprofloxacin in long-lasting otorrhea.
    Manestar D; Braut T; Velepic M
    Arch Otolaryngol Head Neck Surg; 1999 Feb; 125(2):236. PubMed ID: 10037296
    [No Abstract]   [Full Text] [Related]  

  • 4. Cutaneous anthrax: a concise review.
    Tutrone WD; Scheinfeld NS; Weinberg JM
    Cutis; 2002 Jan; 69(1):27-33. PubMed ID: 11829175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral ciprofloxacin to treat bacterial peritonitis associated with peritoneal dialysis.
    Goffin E; Pouthier D; Vandercam B; Gigi J; van Ypersele de Strihou C
    Clin Nephrol; 1997 Dec; 48(6):391-2. PubMed ID: 9438101
    [No Abstract]   [Full Text] [Related]  

  • 6. A prospective, controlled, randomized, non-blind, comparative study of the efficacy and safety of a once daily high dose of ceftriaxone plus ciprofloxacin versus thrice daily ceftazidime plus amikacin in empirical therapy for febrile neutropenic patients.
    Metallidis S; Kollaras P; Giannakakis T; Seitanidis B; Kordosis T; Nikolaidis J; Hatzitolios A; Nikolaidis P
    Eur J Intern Med; 2008 Dec; 19(8):619-24. PubMed ID: 19046729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Single dose ciprofloxacin in cholera.
    Usubütün S; Ağalar C; Diri C; Türkyilmaz R
    Eur J Emerg Med; 1997 Sep; 4(3):145-9. PubMed ID: 9426995
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of soft tissue infections in gynecology by comparison 3 vs 7 day therapy with ciprofloxacin.
    Weissenhacher ER; Gotz A; Braun H; Gutschow K; Wachter I
    J Chemother; 1989 Jul; 1(4 Suppl):889. PubMed ID: 16312689
    [No Abstract]   [Full Text] [Related]  

  • 9. A case report of highly suspected ciprofloxacin-induced hepatotoxicity.
    Bhagirath KM
    Turk J Gastroenterol; 2008 Sep; 19(3):204-6. PubMed ID: 19115163
    [No Abstract]   [Full Text] [Related]  

  • 10. Prospective, randomized, controlled study comparing two dosing regimens of gentamicin/oral ciprofloxacin switch therapy for acute pyelonephritis.
    Bailey RR; Begg EJ; Smith AH; Robson RA; Lynn KL; Chambers ST; Barclay ML; Hornibrook J
    Clin Nephrol; 1996 Sep; 46(3):183-6. PubMed ID: 8879853
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of ciprofloxacin as a prophylactic agent in urinary tract infections in renal transplant recipients.
    Moysés Neto M; Costa RS; Reis MA; Ferraz AS; Saber LT; Batista ME; Muglia V; Garcia TM; Figueiredo JF
    Clin Transplant; 1997 Oct; 11(5 Pt 1):446-52. PubMed ID: 9361939
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ciprofloxacin-induced vasculitis.
    Reaño M; Vives R; Rodríguez J; Daroca P; Canto G; Fernández J
    Allergy; 1997 May; 52(5):599-600. PubMed ID: 9201380
    [No Abstract]   [Full Text] [Related]  

  • 13. Safety and tolerability of linezolid in children.
    Saiman L; Goldfarb J; Kaplan SA; Wible K; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S193-200. PubMed ID: 14520146
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Linezolid for the treatment of complicated skin and skin structure infections in children.
    Yogev R; Patterson LE; Kaplan SL; Adler S; Morfin MR; Martin A; Edge-Padbury B; Naberhuis-Stehouwer S; Bruss JB
    Pediatr Infect Dis J; 2003 Sep; 22(9 Suppl):S172-7. PubMed ID: 14520143
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [The effectiveness of ciprofloxacin in bacterial skin infections].
    Meisel C; Blenk H
    Z Hautkr; 1988 Dec; 63(12):1016-22. PubMed ID: 3218288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Ciprofloxacin-induced acute non-oliguric renal failure in patient with chronic glomerulonephritis].
    Paszkowska M; Niemir ZI; Nowak A; Czekalski S
    Wiad Lek; 2005; 58(1-2):131-3. PubMed ID: 15991567
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical efficacy and safety of oral ciprofloxacin in pelvic inflammatory disease.
    De Wilde R
    J Chemother; 1989 Jul; 1(4 Suppl):896-7. PubMed ID: 16312693
    [No Abstract]   [Full Text] [Related]  

  • 18. Dose adjustment of ciprofloxacin in renal failure: reduce the dose or prolong the administration interval?
    Czock D; Rasche FM
    Eur J Med Res; 2005 Apr; 10(4):145-8. PubMed ID: 15946909
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Observational study of therapy compliance in the treatment of uncomplicated urinary tract infections of the urinary tract with 500 mg ciprofloxacin suspension].
    García Victor F; Ferrero Doria R
    Arch Esp Urol; 2001 May; 54(4):313-20. PubMed ID: 11455764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avoiding adverse reactions.
    Lilley LL; Guanci R
    Am J Nurs; 1996 Sep; 96(9):18-20. PubMed ID: 8855906
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.